Leukemia & lymphoma · 2018
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wróbel Tomasz, Biecek Przemysław, Rybka Justyna, Szulgo Anna, Sorbotten Natalia, Giza Agnieszka, Tyczyńska Agata, Nowara Elżbieta, Badora-Rybicka Agnieszka, Adamowicz Krzysztof, Kulikowski Waldemar, Kroll-Balcerzak Renata, Balcerzak Andrzej, Spychałowicz Wojciech, Kalinka-Warzocha Ewa, Kumiega Beata, Drozd-Sokołowska Joanna, Subocz Edyta, Sałek Agata, Machaczka Maciej, Hołojda Jadwiga, Pogrzeba Joanna, Dobrzyńska Olga, Chmielowska Ewa, Jurczak Wojciech, Knopińska-Posłuszny Wanda, Leśniewski-Kmak Krzysztof, Maciej Zaucha Jan
Аннотация
We retrospectively analyzed long-term disease outcome of 350 elderly Hodgkin Lymphoma (eHL) patients treated with ABVD/ABVD-like regimen enrolled in the PLRG-R9 study between 2001 and 2013 in Poland. Complete remission was reported for 73% of early (ES) and 61% advanced stage (AS) patients. Nine (10%) ES and 56 (20%) AS patients have died. With the median follow-up of 36 (1-190) months, 3-year EFS and OS was 0.74 (95%CI: 0.63-0.85) and 0.90 (95%CI: 0.82-0.98) for ES; 0.51 (95%CI: 0.44-0.57), and 0.81 (95%CI: 0.75-0.86) for AS patients, respectively. For ES patients, Cox regression revealed ECOG <2 and age >70 as predictive for inferior OS and EFS. For AS patients, the most predictive for OS was the presence of cardiovascular disorders (CVD) (p = .00044), while for EFS four factors were significantly associated with a poor outcome: ECOG< 2, age >70 years, CVD and extranodal disease. In conclusion, CVD significantly impacts outcomes of ABVD-treated advanced eHL patients.